Covid-19 vaccine (recombinant spike protein, adjuvanted)
- Drugs List
- Therapeutic Indications
- Dosage
- Administration
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Vaccine containing COVID-19 (recombinant spike protein, adjuvanted).
Drugs List
Therapeutic Indications
Uses
Coronavirus disease 2019 (COVID-19): Prophylaxis
For comprehensive information or advice on this product or the immunisation programme in the UK, the following website should be accessed.
Available at https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book
Dosage
Adults
2 doses (0.5ml each), administered 3 weeks apart.
Administration
Administered via intramuscular injection.
Contraindications
Children under 18 years
Precautions and Warnings
Acute infection
Immunosuppression
Recent anticoagulant therapy
Severe febrile conditions
Breastfeeding
Coagulopathy
Immunodeficiency syndromes
Pregnancy
Thrombocytopenia
Postpone immunisation if there is active or suspected infection
Advise ability to drive/operate machinery may be affected by side effects
Avoid second dose if anaphylaxis occurs with first dose
Avoid within 90 days after casirivimab and imdevimab therapy
Impaired response possible in immunocompromised patients
Vaccine may not be effective in 100% of patients
Different brands may not be interchangeable
Do not mix with other vaccines in the same syringe
Record name and batch number of administered product
Resuscitation facilities must be immediately available
Monitor patient for at least 15 minutes after vaccination
Management of cases of shock should follow current medical standards
Follow national immunisation guidelines
If anaphylaxis occurs following the first dose of the vaccine, do not administer the second dose.
Precautions should be in place to avoid injury from fainting should a psychogenic response occur from the needle injection.
Pregnancy and Lactation
Pregnancy
Use COVID-19 vaccine (recombinant spike protein, adjuvanted) with caution during pregnancy.
The manufacturer does not recommend using COVID-19 vaccine (recombinant spike protein, adjuvanted) during pregnancy unless the potential benefits outweigh any potential risks to the mother or foetus. At the time of writing there is limited published information regarding the use of COVID-19 vaccine (recombinant spike protein, adjuvanted) during pregnancy. Potential risks are unknown.
Lactation
Use COVID-19 vaccine (recombinant spike protein, adjuvanted) with caution during breastfeeding.
The presence of COVID-19 vaccine (recombinant spike protein, adjuvanted) in human breast milk and its effects on exposed infants are unknown.
Side Effects
Arthralgia
Chills
Erythema
Fatigue
Headache
Hypertension
Local pain (injection site)
Lymphadenopathy
Malaise
Myalgia
Nausea
Painful extremities
Pruritus
Pyrexia
Rash
Swelling (injection site)
Tenderness (injection site)
Urticaria
Vomiting
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: February 2022
Reference Sources
Summary of Product Characteristics: Nuvaxovid dispersion for injection. Novavax. Revised February 2022.
Immunisation against infectious disease - The Green Book.
Available at https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book
Last accessed: 10 February 2022.
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.